Navigation Links
Sorafenib Shows Promise for Heart-Lung Disease

Cancer drug interferes with abnormal cell growth seen in pulmonary hypertension

TUESDAY, May 20 (HealthDay News) -- The cancer drug sorafenib (Nexavar) shows promise as a treatment for pulmonary hypertension, according to a University of Chicago Medical Center study.

During the study, nine patients took the drug for 16 weeks at doses lower than those given to cancer patients. The patients also continued to take their standard medications.

Eight of the patients increased their ability to exercise, six showed significant improvements in their right ventricular ejection fraction (the ability of the heart to pump blood to the lungs), and four had a significant decrease in pulmonary artery pressures.

The most common side effects were diarrhea and hair loss.

The findings were expected to be presented May 20 at the American Thoracic Society annual meeting, in Toronto.

"This is not a disease where we are used to seeing people who have been stable on the strongest medications we have suddenly get better. We have drugs that may slow progression of the disease, but nothing that can stop or reverse the process," study author Dr. Mardi Gomberg-Maitland, an assistant professor of medicine, said in a prepared statement.

"To see these improvements in such a short time is quite promising. Although evaluation of this drug is at a very early stage, and this study focused on safety and tolerability, we are genuinely excited about the results," Gomberg-Maitland said.

Sorafenib was originally developed at the University of Chicago as a treatment for kidney cancer. Both cancer and pulmonary hypertension involve abnormal cell growth. In pulmonary hypertension, the abnormal cell growth occurs in blood vessels that lead to the lungs, causing the vessels to thicken and narrow. This means the heart has to work harder to pump blood to the lungs. This extra workload damages the heart.

Sorafenib appears to interfere with the abnormal cell growth seen in pulmonary hypertension.

Researchers are now organizing a multi-center trial of the drug in patients with pulmonary hypertension.

More information

The U.S. National Heart, Lung, and Blood Institute has more about pulmonary hypertension.

-- Robert Preidt

SOURCE: University of Chicago Medical Center, news release, May 19, 2008

Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Analysis shows combining sorafenib with carboplatin/paclitaxel adds no benefit in lung cancer
2. Sorafenib Slows Growth of Some Leukemias
3. With age comes a sense of peace and calm, population research center study shows
4. Iressa shows promise for treatment of metastatic breast cancer when combined with hormonal therapy
5. Study shows that administering calcium and magnesium effectively reduces neurological sensitivity
6. Celebrex shows benefit in first-of-its-kind lung cancer chemoprevention trial
7. Having Less Power Impairs the Mind and Ability to Get Ahead, Study Shows
8. Kids Growing Up on Grown Up Drugs: New Research Shows Treatments for Adult Ailments Rapidly Rising in Children
9. Avalere Report Shows Unapproved Prescription Drugs Dropped from CMS Formulary Reference File
10. New Survey Shows Americans Value Oral Health But Knowledge Gap Remains
11. Research shows HPV testing offers women protection for twice as long as smear testing
Post Your Comments:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... ... fertility once they have been diagnosed with endometriosis. These women need a treatment ... also require a comprehensive approach that can help for preservation of fertility and ...
(Date:6/25/2016)... ... 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can ... CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn ... X . Simply select a ProHand generator and drag it above media or text ...
(Date:6/25/2016)... ... 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the ... to iHire in recognition of their exemplary accomplishments in worksite health promotion. , The ... Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell ... pain and the benefits of holistic treatments, Serenity Recovery Center of Marne, ... Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, ... treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including robotic ... osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
(Date:6/23/2016)...  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... . ... ... ... Astellas ...
(Date:6/23/2016)... Tenn. , June 23, 2016 /PRNewswire/ ... automating, integrating and transforming the patient payment ... of several innovative new products and services ... of its revenue cycle offerings. These award-winning ... more efficient workflows, remain compliant in an ...
Breaking Medicine Technology: